Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Study identifies most common genetic cause of Parkinson’s
The study, conducted by Dr William Nichols, a geneticist at Cincinnati Children’s Hospital Medical Center, has been published in the medical journal The Lancet, as well as studies
The study, conducted by Dr William Nichols, a geneticist at Cincinnati Children’s Hospital Medical Center, has been published in the medical journal The Lancet, as well as studies
Telomeres are DNA sequences found at the ends of chromosomes that play a key role in controlling the life span of cells. With every cell division, telomeres get
Advanced melanoma can be successfully treated in some cases by vaccinating patients with tumor proteins. How these vaccines work and why they are only effective in some patients
Sleep-disordered breathing in children is most commonly caused by enlarged adenoids and tonsils, which is cured by tonsillectomy and adenoidectomy (T&A) surgery in the majority of cases. Dr
Under the terms of the agreement, in exchange for the assets of SurroMed’s biomarker business, PPD will surrender for cancellation its shares of SurroMed preferred stock, will assume
The license agreement enables MycoLogics to enter into proof of concept pre-clinical testing of human and animal candidate vaccines targeting the fungal diseases aspergillosis, coccidioidmycosis, cryptococcosis and the
This is one of the final steps in Shire’s divestment program – designed to ensure focus on later stage pipeline investment in its core therapeutic areas of CNS,
The new dosage will be 0.5mg of norethindrone acetate and 2.5mcg of ethinyl estradiol. This new lower dose is half the dose of the currently marketed Femhrt 1mg/5mcg.
The product has been approved with a once-daily designation for use in a dose range from 100 to 400mg per day in the treatment of moderate to severe
With enrollment closed, Pro-Pharmaceuticals is focused on finishing the treatment and evaluation of patients in the trial. The trial is expected to evaluate up to a total of